A detailed history of Tower Research Capital LLC (Trc) transactions in Replimune Group, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 850 shares of REPL stock, worth $10,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
850
Previous 27,383 96.9%
Holding current value
$10,625
Previous $246,000 96.34%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.09 - $11.23 $214,651 - $297,965
-26,533 Reduced 96.9%
850 $9,000
Q2 2024

Aug 13, 2024

BUY
$5.01 - $9.46 $122,349 - $231,022
24,421 Added 824.48%
27,383 $246,000
Q1 2024

May 15, 2024

SELL
$6.87 - $9.31 $8,553 - $11,590
-1,245 Reduced 29.59%
2,962 $24,000
Q4 2023

Feb 13, 2024

BUY
$6.75 - $16.18 $19,966 - $47,860
2,958 Added 236.83%
4,207 $35,000
Q3 2023

Nov 14, 2023

SELL
$15.96 - $22.18 $118,758 - $165,041
-7,441 Reduced 85.63%
1,249 $21,000
Q2 2023

Aug 14, 2023

BUY
$15.65 - $24.1 $34,383 - $52,947
2,197 Added 33.84%
8,690 $201,000
Q1 2023

May 09, 2023

BUY
$17.48 - $29.09 $67,769 - $112,781
3,877 Added 148.2%
6,493 $115,000
Q4 2022

Feb 10, 2023

SELL
$17.09 - $27.91 $108,743 - $177,591
-6,363 Reduced 70.87%
2,616 $72,000
Q3 2022

Nov 10, 2022

BUY
$15.6 - $21.15 $3,322 - $4,504
213 Added 2.43%
8,979 $155,000
Q2 2022

Aug 15, 2022

SELL
$13.32 - $19.98 $169,550 - $254,325
-12,729 Reduced 59.22%
8,766 $153,000
Q1 2022

May 12, 2022

BUY
$15.24 - $29.75 $252,298 - $492,511
16,555 Added 335.12%
21,495 $365,000
Q4 2021

Feb 14, 2022

BUY
$25.43 - $34.25 $68,254 - $91,927
2,684 Added 118.97%
4,940 $134,000
Q3 2021

Nov 15, 2021

SELL
$28.98 - $39.54 $96,619 - $131,826
-3,334 Reduced 59.64%
2,256 $67,000
Q2 2021

Aug 16, 2021

BUY
$28.5 - $39.37 $99,550 - $137,519
3,493 Added 166.57%
5,590 $215,000
Q1 2021

May 17, 2021

BUY
$30.22 - $45.57 $41,038 - $61,884
1,358 Added 183.76%
2,097 $64,000
Q4 2020

Feb 16, 2021

SELL
$23.5 - $52.65 $409,135 - $916,636
-17,410 Reduced 95.93%
739 $29,000
Q3 2020

Nov 16, 2020

BUY
$18.85 - $27.0 $283,899 - $406,647
15,061 Added 487.73%
18,149 $418,000
Q2 2020

Aug 13, 2020

BUY
$9.76 - $25.95 $15,586 - $41,442
1,597 Added 107.11%
3,088 $77,000
Q1 2020

May 15, 2020

BUY
$8.9 - $19.08 $13,269 - $28,448
1,491 New
1,491 $15,000
Q4 2019

Feb 07, 2020

SELL
$11.61 - $17.21 $6,350 - $9,413
-547 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$10.01 - $16.87 $5,475 - $9,227
547 New
547 $8,000
Q2 2019

Aug 13, 2019

SELL
$12.51 - $17.28 $10,270 - $14,186
-821 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$10.26 - $16.24 $30,041 - $47,550
-2,928 Reduced 78.1%
821 $12,000
Q4 2018

Feb 14, 2019

BUY
$9.97 - $15.57 $17,836 - $27,854
1,789 Added 91.28%
3,749 $37,000
Q3 2018

Nov 13, 2018

BUY
$14.99 - $22.14 $29,380 - $43,394
1,960 New
1,960 $32,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.